Novadigm Therapeutics Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • 2ndary - Private

Novadigm Therapeutics General Information

Description

Operators of an immunotherapeutic firm intended to protect people from fungal and bacterial diseases. The company develops preventative vaccines containing a recombinant form of the albicans agglutinin-like sequence 3 (Als3) surface protein, which facilitates adherence to and invasion of human endothelial cells to reduce the severity of disease caused by both fungal and bacterial pathogens, enabling healthcare professionals to make patients immune before being attacked by the disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 1622A Beacon Street
  • Suite 302
  • Brookline, MA 02446
  • United States
+1 (701)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 1622A Beacon Street
  • Suite 302
  • Brookline, MA 02446
  • United States
+1 (701)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novadigm Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 01-Mar-2021 Completed Generating Revenue
6. Grant 02-Jun-2017 Completed Generating Revenue
5. Later Stage VC (Series B) 03-Oct-2013 Completed Generating Revenue
4. Later Stage VC 20-Feb-2013 Completed Generating Revenue
3. Grant Completed Generating Revenue
2. Grant 31-Dec-2009 $240K $18.1M Completed Generating Revenue
1. Early Stage VC (Series A) 27-Jun-2008 $18.1M $18.1M Completed Generating Revenue
To view Novadigm Therapeutics’s complete valuation and funding history, request access »

Novadigm Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Novadigm Therapeutics’s complete cap table history, request access »

Novadigm Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operators of an immunotherapeutic firm intended to protect people from fungal and bacterial diseases. The company develo
Biotechnology
Brookline, MA
3 As of 2017

Barcelona, Spain
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novadigm Therapeutics Competitors (11)

One of Novadigm Therapeutics’s 11 competitors is Ona Therapeutics, a Venture Capital-Backed company based in Barcelona, Spain.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ona Therapeutics Venture Capital-Backed Barcelona, Spain
Volastra Venture Capital-Backed New York, NY
Avalyn Pharma Formerly VC-backed Boston, MA
Ability Pharma Private Equity-Backed Cerdanyola, Spain
Merck & Co. Corporation Rahway, NJ
You’re viewing 5 of 11 competitors. Get the full list »

Novadigm Therapeutics Patents

Novadigm Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3426287-A1 Methods and kits for use in preventing and treating vulvovaginal candidiasis Inactive 09-Mar-2016
EP-3426287-A4 Methods and kits for use in preventing and treating vulvovaginal candidiasis Inactive 09-Mar-2016
US-10857216-B2 Methods and kits for use in preventing and treating vulvovaginal candidiasis Active 09-Mar-2016
US-20190076512-A1 Methods and kits for use in preventing and treating vulvovaginal candidiasis Active 09-Mar-2016
WO-2017155949-A1 Methods and kits for use in preventing and treating vulvovaginal candidiasis Inactive 09-Mar-2016 A61K39/0002
To view Novadigm Therapeutics’s complete patent history, request access »

Novadigm Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novadigm Therapeutics FAQs

  • When was Novadigm Therapeutics founded?

    Novadigm Therapeutics was founded in 2005.

  • Where is Novadigm Therapeutics headquartered?

    Novadigm Therapeutics is headquartered in Brookline, MA.

  • What is the size of Novadigm Therapeutics?

    Novadigm Therapeutics has 3 total employees.

  • What industry is Novadigm Therapeutics in?

    Novadigm Therapeutics’s primary industry is Biotechnology.

  • Is Novadigm Therapeutics a private or public company?

    Novadigm Therapeutics is a Private company.

  • What is Novadigm Therapeutics’s current revenue?

    The current revenue for Novadigm Therapeutics is .

  • How much funding has Novadigm Therapeutics raised over time?

    Novadigm Therapeutics has raised $52.7M.

  • Who are Novadigm Therapeutics’s competitors?

    Ona Therapeutics, Volastra, Avalyn Pharma, Ability Pharma, and Merck & Co. are some of the 11 competitors of Novadigm Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process